Expand ELTX Menu
ELTX MENU

ELTX Stock Posts


Unusual Option Volume

ELTX Elicio Therapeutics3.94+0.09 (+2.3%)

Elicio Therapeutics trades 3,648 contracts. The highest volume is in the 20-Nov-26 12.5 puts, which is -217.3% below the current price.
View Details...
Unusual Option Volume

ELTX Elicio Therapeutics4.47+1.71 (+62.0%)

Elicio Therapeutics trades 3,932 contracts. The company has the following event: Elicio Therapeutics Virtual KOL Event on Jun 24, 2026. News: Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
View Details...
ELTX #ElicioTherapeutics stock declines -23.0% in premarket,

Premarket Decliner

ELTX Elicio Therapeutics2.76-1.32-32.4%

Premarket:2.13-0.63 (-23.0%)

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

Globe NewswireWed, 17-Jun 8:00 AM
Unusual Option Volume

ELTX Elicio Therapeutics3.35-0.73 (-17.9%)

Elicio Therapeutics trades 2,591 contracts.
View Details...
Unusual Option Volume

ELTX Elicio Therapeutics4.00-10.85 (-73.1%)

Elicio Therapeutics trades 8,479 contracts. The company has the following event: Elicio Therapeutics Conference Call and Webcast on AMPLIFY-7P Results and Phase 3 Strategy on Jun 15, 2026. News: Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
View Details...
ELTX #ElicioTherapeutics stock declines -54.8% in premarket,

Premarket Decliner

ELTX Elicio Therapeutics14.85+0.91+6.5%

Premarket:6.71-8.14 (-54.8%)

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Globe NewswireMon, 15-Jun 7:00 AM
Load Earlier Posts
Market Data Delayed 15 Minutes